glp-1 news 2025 november As Drugs Go Mainstream, This Expert Says Health is More than a Number on a Scale GLP-1 Pipeline Update: August 2025

The SURPASS-1 trial demonstrated significant improvements in glycemic control and substantial reductions in body weight with all three doses of tirzepatide (5 mg, 10 mg, or 15 mg) compared to placebo over a 40-week period

Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice

Glucagon-like peptide-1 receptor agonists and suicidal ideation: analysis of real-word data collected in the european pharmacovigilance database

H.HerzM.HiguchiT.et al (2015)

Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study

This partnership focuses on enhancing pharmaceutical packaging by improving filling-line efficiency by 2050% and reducing glass particulates, cracks, and cosmetic defects